Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OX-40 ligand (OX40L), also known as CD252 or TNFSF4 (tumor necrosis factor ligand superfamily member 4), is a type II transmembrane glycoprotein and an endogenous protein in humans. It is the natural ligand for the receptor OX40 (CD134/TNFRSF4), which is expressed on activated T cells. OX40L itself is stably expressed on antigen-presenting cells such as dendritic cells (especially DC2s), macrophages, activated B lymphocytes, and some non-immune cells like endothelial and smooth muscle cells[1][2][5]. The interaction between OX40 and its ligand delivers a late co-stimulatory signal that promotes T cell activation, survival, proliferation of activated CD4+ T cells, development of memory T cells and polarization towards Th2 immune responses[1][5][7]. This pathway plays a critical role in adaptive immunity. Modulation of the OX40/OX40L axis has been explored for therapeutic purposes in cancer immunotherapy as well as autoimmune/inflammatory diseases[2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OX-40 ligand.